Skip to main content

Table 3 Mixed effects, generalised linear model for occurrence of ‘critical haemorrhage’ (intracranial haemorrhage or haemorrhage requiring transfusion matched for propensity for use of ‘enhanced’ prophylaxis

From: Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic: observational report from 28 European intensive care units

  Effect size (log odds) p value 95% CI  
(Intercept) − 3.31  < 0.0001 − 4.41 − 2.21
Use of ‘enhanced’ (therapeutic) prophylaxis 0.187 0.64 − 0.591 0.964
Age (years) − 3.57 0.1 − 7.85 0.713
BMI − 0.83 0.41 − 2.79 1.13
History of hypertension − 0.0719 0.86 − 0.879 0.736
History of diabetes − 0.341 0.55 − 1.47 0.792
History of renal disease − 0.374 0.73 − 2.52 1.77
Intubated − 0.757 0.38 − 2.44 0.931
D-dimer at ICU_admission − 7960 0.33 − 24,000 8070
P/F ratio at ICU admission 8.38 0.62 − 24.6 41.3
CRP at ICU admission 27.7 0.32 − 27 82.4
Fibrinogen at ICU_admission − 89.9 0.14 − 210 30.2
Platelet count at_ICU_admission 2.71 0.91 − 44.6 50
WBC at ICU admission 2.11 0.039 0.11 4.12
Antiplatelet agent use 0.666 0.2 − 0.358 1.69
  1. Effect sizes are unscaled log odds (positive indicates associate with increased risk of critical haemorrhage)
  2. BMI, body mass index; ICU, intensive care unit; P/F partial pressure of oxygen/inspired fraction of oxygen; CRP, C-reactive protein; WBC, white blood cells